PL3712152T3 - Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych - Google Patents
Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowychInfo
- Publication number
- PL3712152T3 PL3712152T3 PL20171633T PL20171633T PL3712152T3 PL 3712152 T3 PL3712152 T3 PL 3712152T3 PL 20171633 T PL20171633 T PL 20171633T PL 20171633 T PL20171633 T PL 20171633T PL 3712152 T3 PL3712152 T3 PL 3712152T3
- Authority
- PL
- Poland
- Prior art keywords
- hexahydroimidazo
- imidazo
- tetrahydro
- pyridine
- kinase inhibitors
- Prior art date
Links
- YGGJYQPWXRLNBA-UHFFFAOYSA-N 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine Chemical class C1CNCCC2=C1NC=N2 YGGJYQPWXRLNBA-UHFFFAOYSA-N 0.000 title 1
- URMVFILWXLQJIP-UHFFFAOYSA-N 4,5,6,7-tetrahydro-3h-imidazo[4,5-c]pyridine Chemical compound C1NCCC2=C1NC=N2 URMVFILWXLQJIP-UHFFFAOYSA-N 0.000 title 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1519381.6A GB201519381D0 (en) | 2015-11-03 | 2015-11-03 | Kinase inhibitors |
| GB201606968 | 2016-04-21 | ||
| EP20171633.9A EP3712152B1 (en) | 2015-11-03 | 2016-11-02 | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| PCT/GB2016/053387 WO2017077283A1 (en) | 2015-11-03 | 2016-11-02 | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| EP16793973.5A EP3371184A1 (en) | 2015-11-03 | 2016-11-02 | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3712152T3 true PL3712152T3 (pl) | 2021-08-02 |
Family
ID=57256356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20171633T PL3712152T3 (pl) | 2015-11-03 | 2016-11-02 | Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10851097B2 (pl) |
| EP (3) | EP3371184A1 (pl) |
| CA (1) | CA3037243A1 (pl) |
| DK (1) | DK3712152T3 (pl) |
| ES (1) | ES2864035T3 (pl) |
| PL (1) | PL3712152T3 (pl) |
| PT (1) | PT3712152T (pl) |
| WO (1) | WO2017077283A1 (pl) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2840650T3 (es) | 2015-11-03 | 2021-07-07 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus |
| KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
| EA037748B1 (ru) | 2017-03-09 | 2021-05-18 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Конденсированные имидазо-пиперидиновые ингибиторы jak |
| MY200348A (en) | 2017-05-01 | 2023-12-21 | Theravance Biopharma R&D Ip Llc | Crystalline forms of a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| SG11201909019SA (en) | 2017-05-01 | 2019-10-30 | Theravance Biopharma R&D Ip Llc | Methods of treatment using a jak inhibitor compound |
| US10392368B2 (en) | 2017-08-01 | 2019-08-27 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| KR102826491B1 (ko) | 2018-09-04 | 2025-06-27 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 |
| BR112021004087A2 (pt) * | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | processo para preparar inibidores de jak e seus intermediários |
| US10836763B2 (en) * | 2018-09-04 | 2020-11-17 | Theravance Biopharma R&D Ip, Llc | 5 to 7 membered heterocyclic amides as JAK inhibitors |
| JP2022506111A (ja) * | 2018-10-29 | 2022-01-17 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Jak阻害剤としての2-アザビシクロヘキサン化合物 |
| CA3125039A1 (en) * | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| SI3932919T1 (sl) | 2019-02-25 | 2024-09-30 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Spojina inhibitorja JAK in njena uporaba |
| CN114075200A (zh) * | 2020-08-14 | 2022-02-22 | 河南迈英诺医药科技有限公司 | 用于治疗重症肺炎的jak抑制剂化合物 |
| CN114075199B (zh) * | 2020-08-14 | 2026-03-10 | 河南迈英诺医药科技有限公司 | Jak抑制剂化合物及其用途 |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| US20240317760A1 (en) * | 2021-06-21 | 2024-09-26 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Trk kinase inhibitor compound and use thereof |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| US20250387388A1 (en) * | 2022-07-04 | 2025-12-25 | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. | Compound as trk inhibitor and/or ret inhibitor and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009007839A1 (en) | 2007-07-11 | 2009-01-15 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| FR2981917B1 (fr) | 2011-10-26 | 2013-11-15 | Cadorit Ag | Recipient pour emballer un premier fluide et un deuxieme fluide |
| JP6248103B2 (ja) | 2012-06-22 | 2017-12-13 | ミメトゲン ファーマシュウティカルズ インコーポレイテッドMimetogen Pharmaceuticals, Inc. | β−ターン環式ペプチド模倣化合物の合成 |
| EP3143021B1 (en) | 2014-05-14 | 2019-06-12 | Pfizer Inc | Pyrazolopyridines and pyrazolopyrimidines |
| JP6692836B2 (ja) | 2015-05-28 | 2020-05-13 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Jakキナーゼ阻害剤としてのナフチリジン化合物 |
| ES2840650T3 (es) | 2015-11-03 | 2021-07-07 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus |
| KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
| AU2016359494B2 (en) | 2015-11-24 | 2021-01-07 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease |
| WO2017189822A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
-
2016
- 2016-11-02 EP EP16793973.5A patent/EP3371184A1/en not_active Withdrawn
- 2016-11-02 US US15/772,861 patent/US10851097B2/en not_active Expired - Fee Related
- 2016-11-02 EP EP21151168.8A patent/EP3865481A1/en not_active Withdrawn
- 2016-11-02 EP EP20171633.9A patent/EP3712152B1/en not_active Not-in-force
- 2016-11-02 PT PT201716339T patent/PT3712152T/pt unknown
- 2016-11-02 DK DK20171633.9T patent/DK3712152T3/da active
- 2016-11-02 ES ES20171633T patent/ES2864035T3/es active Active
- 2016-11-02 PL PL20171633T patent/PL3712152T3/pl unknown
- 2016-11-02 WO PCT/GB2016/053387 patent/WO2017077283A1/en not_active Ceased
- 2016-11-02 CA CA3037243A patent/CA3037243A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3865481A1 (en) | 2021-08-18 |
| WO2017077283A1 (en) | 2017-05-11 |
| DK3712152T3 (da) | 2021-03-22 |
| US10851097B2 (en) | 2020-12-01 |
| CA3037243A1 (en) | 2017-05-11 |
| PT3712152T (pt) | 2021-04-15 |
| EP3712152B1 (en) | 2021-01-13 |
| EP3712152A1 (en) | 2020-09-23 |
| ES2864035T3 (es) | 2021-10-13 |
| EP3371184A1 (en) | 2018-09-12 |
| US20180319791A1 (en) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3712152T3 (pl) | Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych | |
| PT3371185T (pt) | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase | |
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| IL265918A (en) | Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors | |
| ZA201800771B (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| LT3555097T (lt) | Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai | |
| IL257886B (en) | History of imidazo[5,4-c]quinoline and imidazo[5,4-c][5,1]naphthyridine as lrrk2 inhibitors | |
| SMT202300273T1 (it) | Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso | |
| ZA201704494B (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | |
| ZA201808257B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| MY185392A (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| IL269214B (en) | Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors | |
| IL247948B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors | |
| EP2970278A4 (en) | Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9- | |
| IL290419A (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
| IL269215A (en) | Disubstituted imidazole[4,5-C]quinoline derivatives | |
| HK1238236A1 (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors |